Komipharm International Co., Ltd. (KOSDAQ:041960)
South Korea · Delayed Price · Currency is KRW 8,410.00
-60.00 (-0.71%)
Apr 10, 2026, 3:30 PM KST
Komipharm International Revenue
In the year 2025, Komipharm International had annual revenue of 52.47B KRW, down -10.74%. Komipharm International had revenue of 11.90B in the quarter ending December 31, 2025, a decrease of -24.38%.
Revenue
52.47B
Revenue Growth
-10.74%
P/S Ratio
11.60
Revenue / Employee
325.87M
Employees
161
Market Cap
608.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.47B | -6.31B | -10.74% |
| Dec 31, 2024 | 58.78B | 16.13B | 37.83% |
| Dec 31, 2023 | 42.65B | 2.85B | 7.15% |
| Dec 31, 2022 | 39.80B | 3.95B | 11.03% |
| Dec 31, 2021 | 35.85B | -1.31B | -3.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 3.02T |
| Green Cross Holdings | 2.45T |
| Dong-A Socio Holdings | 1.43T |
| i-SENS | 315.44B |
| Shinpoong Pharmaceutical Co.,Ltd | 234.68B |
| ALTEOGEN | 215.86B |